IMITREX STATDOSE Drug Patent Profile
✉ Email this page to a colleague
When do Imitrex Statdose patents expire, and what generic alternatives are available?
Imitrex Statdose is a drug marketed by Glaxosmithkline and is included in one NDA.
The generic ingredient in IMITREX STATDOSE is sumatriptan succinate. There are twenty-four drug master file entries for this compound. Thirty-five suppliers are listed for this compound. Additional details are available on the sumatriptan succinate profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Imitrex Statdose
A generic version of IMITREX STATDOSE was approved as sumatriptan succinate by WEST-WARD PHARMS INT on February 6th, 2009.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for IMITREX STATDOSE?
- What are the global sales for IMITREX STATDOSE?
- What is Average Wholesale Price for IMITREX STATDOSE?
Summary for IMITREX STATDOSE
| US Patents: | 0 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 2 |
| Raw Ingredient (Bulk) Api Vendors: | 115 |
| Clinical Trials: | 2 |
| Patent Applications: | 2,223 |
| Drug Prices: | Drug price information for IMITREX STATDOSE |
| DailyMed Link: | IMITREX STATDOSE at DailyMed |
Recent Clinical Trials for IMITREX STATDOSE
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| GlaxoSmithKline | Phase 1 |
| Diamond Headache Clinic | Phase 4 |
| GlaxoSmithKline | Phase 4 |
Pharmacology for IMITREX STATDOSE
| Drug Class | Serotonin-1b and Serotonin-1d Receptor Agonist |
| Mechanism of Action | Serotonin 1b Receptor Agonists Serotonin 1d Receptor Agonists |
US Patents and Regulatory Information for IMITREX STATDOSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Glaxosmithkline | IMITREX STATDOSE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-002 | Feb 1, 2006 | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | ||||
| Glaxosmithkline | IMITREX STATDOSE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-003 | Dec 23, 1996 | AB | RX | Yes | Yes | ⤷ Subscribe | ⤷ Subscribe | ⤷ Subscribe | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for IMITREX STATDOSE
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Glaxosmithkline | IMITREX STATDOSE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-002 | Feb 1, 2006 | ⤷ Subscribe | ⤷ Subscribe |
| Glaxosmithkline | IMITREX STATDOSE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-003 | Dec 23, 1996 | ⤷ Subscribe | ⤷ Subscribe |
| Glaxosmithkline | IMITREX STATDOSE | sumatriptan succinate | INJECTABLE;SUBCUTANEOUS | 020080-003 | Dec 23, 1996 | ⤷ Subscribe | ⤷ Subscribe |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for IMITREX STATDOSE
See the table below for patents covering IMITREX STATDOSE around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Spain | 523039 | ⤷ Subscribe | |
| U.S.S.R. | 1498386 | CПOCOБ ПOЛУЧEHИЯ 3-[2-(ДИMETИЛAMИHO)-ЭTИЛ]- N-METИЛ-1 H- ИHДOЛ-5-METAHCУЛЬФOHAMИДA ИЛИ EГO COЛEЙ, ИЛИ COЛЬBATOB (METHOD OF PRODUCING 3-/2-(DIMETHYLAMINO)-ETHYL/-N-METHYL-1N-INVOL-5-METHANE SULFONAMIDE OR ITS SALTS OR SOLVATES) | ⤷ Subscribe |
| Ireland | 58122 | An indole derivative | ⤷ Subscribe |
| France | 2568571 | DERIVE D'INDOLE | ⤷ Subscribe |
| Cyprus | 1475 | AN INDOLE DERIVATIVE | ⤷ Subscribe |
| Hungary | 201738 | PROCESS FOR PRODUCING N-METHYL-3-[2-(DIMETHYL-AMINO)-ETHIL]-1H-INDOL-5-METANSULFONAMID DERIVATIVES AND PHARMACEUTICAL PREPARATIONS CONTAINING THE COMPOUNDS | ⤷ Subscribe |
| Japan | H0623197 | ⤷ Subscribe | |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
